Literature DB >> 31386593

The Role of the Microbiome in Drug Response.

Rosina Pryor1,2, Daniel Martinez-Martinez1,2, Leonor Quintaneiro1,2,3, Filipe Cabreiro1,2.   

Abstract

The microbiome is known to regulate many aspects of host health and disease and is increasingly being recognized as a key mediator of drug action. However, investigating the complex multidirectional relationships between drugs, the microbiota, and the host is a challenging endeavor, and the biological mechanisms that underpin these interactions are often not well understood. In this review, we outline the current evidence that supports a role for the microbiota as a contributor to both the therapeutic benefits and side effects of drugs, with a particular focus on those used to treat mental disorders, type 2 diabetes, and cancer. We also provide a snapshot of the experimental and computational tools that are currently available for the dissection of drug-microbiota-host interactions. The advancement of knowledge in this area may ultimately pave the way for the development of novel microbiota-based strategies that can be used to improve treatment outcomes.

Entities:  

Keywords:  antipsychotics; cancer; drugs; metabolism; metformin; microbiome

Mesh:

Year:  2019        PMID: 31386593     DOI: 10.1146/annurev-pharmtox-010919-023612

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  11 in total

Review 1.  Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

Authors:  Frederik Soetaert; Preethi Korangath; David Serantes; Steven Fiering; Robert Ivkov
Journal:  Adv Drug Deliv Rev       Date:  2020-06-27       Impact factor: 15.470

Review 2.  C. elegans: A biosensor for host-microbe interactions.

Authors:  Cassandra Backes; Daniel Martinez-Martinez; Filipe Cabreiro
Journal:  Lab Anim (NY)       Date:  2021-03-01       Impact factor: 12.625

Review 3.  Therapies from Fucoidan: New Developments.

Authors:  Helen J Fitton; Damien S Stringer; Ah Young Park; Samuel N Karpiniec
Journal:  Mar Drugs       Date:  2019-10-09       Impact factor: 5.118

4.  Evolved bacterial resistance against fluoropyrimidines can lower chemotherapy impact in the Caenorhabditis elegans host.

Authors:  Brittany Rosener; Serkan Sayin; Peter O Oluoch; Aurian P García González; Hirotada Mori; Albertha Jm Walhout; Amir Mitchell
Journal:  Elife       Date:  2020-11-30       Impact factor: 8.140

Review 5.  Towards a mechanistic understanding of reciprocal drug-microbiome interactions.

Authors:  Michael Zimmermann; Kiran Raosaheb Patil; Athanasios Typas; Lisa Maier
Journal:  Mol Syst Biol       Date:  2021-03       Impact factor: 11.429

6.  An overview of machine learning methods for monotherapy drug response prediction.

Authors:  Farzaneh Firoozbakht; Behnam Yousefi; Benno Schwikowski
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

Review 7.  Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs.

Authors:  Wuwen Feng; Juan Liu; Hui Ao; Shijun Yue; Cheng Peng
Journal:  Theranostics       Date:  2020-09-14       Impact factor: 11.556

Review 8.  Tissue regulatory T cells.

Authors:  Prudence PokWai Lui; Inchul Cho; Niwa Ali
Journal:  Immunology       Date:  2020-06-24       Impact factor: 7.397

Review 9.  The Interplay between the Host Microbiome and Pathogenic Viral Infections.

Authors:  Rubén González; Santiago F Elena
Journal:  mBio       Date:  2021-11-02       Impact factor: 7.867

10.  Comparative analysis of oral-gut microbiota between captive and wild long-tailed macaque in Thailand.

Authors:  Vorthon Sawaswong; Kesmanee Praianantathavorn; Prangwalai Chanchaem; Ariya Khamwut; Taratorn Kemthong; Yuzuru Hamada; Suchinda Malaivijitnond; Sunchai Payungporn
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.